Is this you? As a journalist, you can create a free Muck Rack account to customize your profile, list your contact preferences, and upload a portfolio of your best work.
Claim your profile
Articles by Peter Sever
Skutki uboczne leków na nadciśnienie. Znany profesor bada to od 40 lat. Zwraca uwagę na nieoczywiste ryzyko
Od ponad 40 lat zajmuję się badaniami nad nadciśnieniem tętniczym i chorobami układu krążenia. Po raz pierwszy zainteresowałem się tą dziedziną medycyny pod koniec lat 70. XX w. podczas wizyty w RPA. Odkryłem wówczas, że mieszkańcy odległych wiejskich społeczności regionu Transkei, niezależnie od wieku, nie cierpieli na nadciśnienie, nie odnotowywano tam udarów, chorób serca, otyłości ani cukrzycy. Kiedy jednak tylko przenosili się do obszarów miejskich, ich ciśnienie krwi wzrastało.
I’m a pharmacologist. This is what you need to know about blood pressure drugs
; ; ; ; Continue reading More for You
I’m a pharmacologist. This is what you need to know about blood pressure drugs
Our series The Expert View brings you specialist health advice from professionals. In this article, we hear from Prof Peter Sever, a clinical pharmacologist at Imperial College who specialises in cardiology and stroke prevention, about the potential side effects associated with blood pressure treatment. I’ve spent more than 40 years researching hypertension (high blood pressure) and cardiovascular disease.
A sham-controlled randomised trial evaluating the safety, acceptability, and efficacy of autonomic neuromodulation using transcutaneous vagal sensory stimulation in uncontrolled hypertensive patients: rationale and study design of the SCRATCH-HTN study
Abstract Background: Despite the broad availability of antihypertensive drugs, approximately 40% of hypertensive patients fail to achieve the recommended blood pressure (BP) levels and may require alternative treatment(s). At present, renal denervation is the only proven non-pharmacological device-based alternative treatment available, but it is a costly, invasive, hospital-based procedure that is unlikely to be widely available.
Ibanly Taps Sumsub for Enhanced Identity Verification
A fintech company specialising in cross border payments, Ibanly taps Sumsub, both pleased to announce a new collaboration today. Ibanly taps Sumsub for identity verification, AML screening, KYC and KYB checks because of the highest quality standards both companies adhere to. This collaboration will allow Ibanly to enhance user onboarding process while ensuring AML compliance with regulatory requirements.
Amlodipine in the current management of hypertension
7.5.2 Black patients CCBs, like amlodipine, or thiazide-type diuretics are recommended as initial therapy for Black patients, including those with diabetes.13 In Nigerian patients with mild, moderate, and severe hypertension treated with amlodipine 5 mg once daily for 2 weeks and increased to 10 mg once daily for 10 weeks, amlodipine was well-tolerated and laboratory tests, including plasma lipids done at the start and end of the trial, remained unchanged.82 Another small, randomized study in...
Sumsub Joins The Payments Association
Sumsub, a global full-cycle verification platform, is honored to announce its membership in The Payments Association. This milestone highlights Sumsub’s ongoing commitment to enhancing compliance measures and offering best-in-class solutions in the vibrant payments ecosystem. As an industry-leading verification provider, Sumsub offers a suite of Know Your Customer (KYC), Know Your Business (KYB), Transaction Monitoring and Fraud Prevention solutions designed to meet the needs of modern businesses.
Severe orthostatic hypotension and weight loss associated with cancer therapy
Two cases of orthostatic hypotension associated with weight loss following cancer treatment are described. Conventional treatments for orthostatic hypotension proved ineffective. A hypothesis of association with skeletal muscle wasting is discussed. Advertisement For healthcare professionals only Case one Professor Peter Sever A squamous cell carcinoma of the right tonsil was confirmed by biopsy in a 70-year-old man in July 2014.
Re: First line drug treatment for hypertension and reductions in blood pressure according to age and ethnicity: cohort study in UK primary care
Dear Editor, The conclusion reached by Sinnott and colleagues (BMJ, November 21, 2020;371:m4080 http://dx.doi.org/10.1136/bmj.m4080), that their analyses fail to confirm the NICE guidelines [1] for the selection of initial antihypertensive drug treatment, based on age and ethnicity, is supported by their observations in contemporary clinical practice in primary care in the UK.
Efficacy and safety of lowering LDL cholesterol in older patients: a systematic review and meta-analysis of randomised controlled trials
Summary Background The clinical benefit of LDL cholesterol lowering treatment in older patients remains debated. We aimed to summarise the evidence of LDL cholesterol lowering therapies in older patients. Methods In this systematic review and meta-analysis, we searched MEDLINE and Embase for articles published between March 1, 2015, and Aug 14, 2020, without any language restrictions.
Michael Schachter
Michael Schachter (“Mike”) was born in, Budapest, Hungary, the youngest of three children (he had two older half sisters). His parents had survived the Holocaust, receiving help from Raoul Wallenberg, the Swedish diplomat and humanitarian. In 1956 after the suppression of the Hungarian revolution, his father left Hungary to move with his wife and Mike to north London where he set-up as a GP.
LDL-cholesterol lowering with evolocumab, and outcomes according to age and sex in patients in the FOURIER Trial
FOURIER was a randomised, double blind trial, comparing evolocumab with placebo in 27,564 patients with atherosclerotic cardiovascular disease receiving statin therapy (median follow-up 2.2 years). The primary endpoint was cardiovascular death, myocardial infarction, stroke, hospitalisation for unstable angina or coronary revascularisation. Cox proportional hazards models were used to assess the efficacy of evolocumab versus placebo stratified by quartiles of patient age and by sex.
William Stanley Peart
Intended for healthcare professionals Toggle navigation The BMJ logo Toggle top menu News & Views William Stanley Peart William Stanley Peart Obituaries BMJ 2019; 367 doi: https://doi.org/10.1136/bmj.l6709 (Published 29 November 2019) Cite this as: BMJ 2019;367:l6709 William Stanley Peart (“Stan”) was born in South Shields, County Durham; he was a Tynesider, whose father was a talented footballer.
Clinical benefits of evolocumab appear less than hoped - Authors' reply
Our analysis1x1Giugliano, RP, Pedersen, TR, Park, J-G et al. Clinical efficacy and safety of achieving very low LDL-cholesterol concentrations with the PCSK9 inhibitor evolocumab: a prespecified secondary analysis of the FOURIER trial. Lancet. 2017; 390: 1962–1971Google ScholarSee all References of the association between LDL-cholesterol concentrations at 4 weeks and cardiovascular outcomes reported in FOURIER2x2Sabatine, MS, Giugliano, RP, Keech, AC et al.
Concerns related to the nocebo effect - Authors' reply
We thank Zhen Zhou and colleagues for their comments on our Article.1As detailed in our Article, we classified all adverse events using the Medical Dictionary for Regulatory Activities and they were further categorised by degree of certainty (definite, probable, or possible) according to prespecified definitions.
Development and Validation of a Model to Predict Absolute Vascular Risk Reduction by Moderate-Intensity Statin Therapy in Individual Patients With Type 2 Diabetes Mellitus
Methods and Results—Data of 2725 patients with type 2 diabetes mellitus from the Lipid Lowering Arm of the Anglo Scandinavian Cardiac Outcomes Trial (ASCOT-LLA) study (atorvastatin 10 mg versus placebo) were used for model derivation. The model was based on 8 clinical predictors including treatment allocation (statin/placebo).
Statins and All-Cause Mortality in High-Risk Primary Prevention: A Meta-analysis of 11 Randomized Controlled Trials Involving 65 229 Participants
Background Statins have been shown to reduce the risk of all-cause mortality among individuals with clinical history of coronary heart disease. However, it remains uncertain whether statins have similar mortality benefit in a high-risk primary prevention setting. Notably, all systematic reviews to date included trials that in part incorporated participants with prior cardiovascular disease (CVD) at baseline.
Show More
loading
Actions
Is this you?
As a journalist, you can create a free Muck Rack account to customize your profile, list your contact preferences, and upload a portfolio of your best work.Get in touch with Peter
Contact Peter, search articles and posts on X, monitor coverage, and track replies from one place.
Learn more about Muck Rack